Melanotan I vs Melanotan II
Melanotan I and Melanotan II share a name, a mechanism category, and a nickname ("the tanning peptide") — but they are fundamentally different drugs with dramatically different safety profiles. One is FDA-approved with 1,000+ patients treated and zero melanoma events. The other is unapproved everywhere, widely sold on the gray market, and linked to documented melanoma case reports. Confusing them is a costly mistake.
Despite similar names and a shared "tanning peptide" nickname, Melanotan I and Melanotan II are very different drugs. Melanotan I (afamelanotide/Scenesse) is FDA-approved, selective for the tanning receptor, and has 1,000+ patients treated with zero melanoma events. Melanotan II is unapproved, non-selective (activates several other receptors including one that causes spontaneous erections and nausea), and is linked to melanoma case reports. Confusing them is dangerous.
Melanotan I
An FDA-approved selective MC1R agonist for erythropoietic protoporphyria (EPP). Stimulates protective eumelanin production without the broad side effects of Melanotan II.
Melanotan II
A synthetic melanocortin peptide studied for tanning, sexual function, and appetite suppression. Not FDA-approved; the FDA has issued public warnings against its use.
| Category | Melanotan I | Melanotan II |
|---|---|---|
| FDA Approval | Yes — approved 2019 as Scenesse for erythropoietic protoporphyria (EPP) | No — never approved in any country, banned as a cosmetic ingredient in multiple jurisdictions |
| Receptor Selectivity | Selective for MC1R (tanning receptor) with minimal activity at MC3R/MC4R | Non-selective — activates MC1R, MC3R, MC4R, and MC5R |
| Structure | 13-amino acid linear analog of alpha-MSH (Nle4, D-Phe7-α-MSH) | 7-amino acid cyclic lactam analog (smaller, more stable, non-selective) |
| Delivery | Subcutaneous bioresorbable implant (16mg) every 60 days — administered by healthcare professional | Self-administered injection or nasal spray (gray market) — no medical oversight |
| Safety Database | 1,000+ patients in clinical trials and post-marketing; zero melanoma events in 10+ years of use | Multiple case reports of melanoma development; all cases involved pre-existing risk factors |
| Mole Changes | Only 2 new nevi reported in 115 patients over 8 years | Darkens and alters existing moles uniformly — interferes with melanoma screening |
| Sexual/Cardiovascular Side Effects | Minimal — selectivity avoids MC4R activation | Spontaneous erections, flushing, nausea, increased libido via MC4R (this is how PT-141 was discovered) |
| Other Side Effects | Implant site reactions, mild headache, nausea (generally mild) | Nausea, fatigue, darkening of existing moles, reports of cerebral edema and kidney dysfunction |
| Cost & Access | Expensive ($10,000+/implant), restricted distribution for EPP only | Cheap ($30-100 per vial on gray market), widely available online despite illegality |
| Regulatory Warnings | FDA-approved with standard monitoring protocols | FDA warning letters, Australian TGA consumer alert, UK Medicines Regulator warning |
| Common Discussion Context | Clinical EPP treatment; rare dermatology indications | Cosmetic tanning, TikTok nasal sprays, gray-market self-use |
In depth
Why receptor selectivity is the whole story
The most important distinction between Melanotan I and Melanotan II isn't their names, their dosing, or their cost — it's which melanocortin receptors they activate. There are five melanocortin receptors in the body, and each one does something different. MC1R lives on skin melanocytes and drives tanning plus DNA repair and protective pigment production. MC2R is in the adrenal cortex. MC3R and MC4R are in the brain and regulate appetite, sexual function, and cardiovascular tone. MC5R is in exocrine glands. A drug that selectively activates only MC1R should produce tanning and photoprotection cleanly; a drug that activates all of them produces tanning plus a grab-bag of off-target effects. Melanotan I is selective for MC1R. Melanotan II is not — it hits MC1R, MC3R, MC4R, and MC5R with roughly comparable affinity. That single difference explains essentially every safety gap between the two drugs.
Safety track records are not comparable
Melanotan I (afamelanotide, brand name Scenesse) has been FDA-approved since 2019 for erythropoietic protoporphyria (EPP) — a rare condition where UV exposure causes severe pain. Over 1,000 patients have been treated in clinical trials and post-marketing surveillance across a decade, with zero melanoma events reported. Only 2 new nevi reported in 115 patients over 8 years. This isn't just "no safety signal yet" — it's a mature, real-world safety database in a defined patient population, with monitored administration by healthcare professionals. Melanotan II's safety story is different. Multiple case reports document melanoma development in users, though the causal link is debated — MT-II may drive melanoma, detect it earlier by darkening moles (users notice changes), or simply co-occur with heavy UV exposure in the same population. What isn't debated: MT-II uniformly darkens moles, which actively interferes with melanoma screening. It causes spontaneous erections and nausea (MC4R activation) — these are not rare side effects; they're the headline complaints. And there are documented cases of cerebral edema and kidney dysfunction, though these remain uncommon.
The MC1R paradox
MC1R activation should reduce melanoma risk, not increase it. People with loss-of-function MC1R variants have 2–4x higher melanoma risk because they can't produce protective eumelanin. Pharmacologically activating MC1R — what afamelanotide does — should be photoprotective. The 1,000+ patient Scenesse dataset validates this direction. The melanoma concerns with MT-II almost certainly come from its non-MC1R activities combined with the gray-market behavior patterns (UV exposure timed to "activate" the tan, unsupervised dosing, no screening) rather than from MC1R activation itself.
Access and regulatory reality
Afamelanotide is expensive ($10,000+ per bioresorbable implant every 60 days), restricted to the EPP indication, and administered by a healthcare professional. Melanotan II is cheap ($30–100 per vial), widely available on gray-market websites, and self-administered via injection or the especially problematic TikTok nasal spray variant. Multiple regulators — FDA, Australia's TGA, UK's MHRA — have issued consumer warnings specifically about MT-II. It is banned as a cosmetic ingredient in multiple jurisdictions. The access gap between the two drugs is not subtle.
Bottom line
For EPP patients, afamelanotide is a life-changing approved medication used under medical supervision. For cosmetic tanning, there is currently no FDA-approved option that solves the "safe tan" problem — afamelanotide could theoretically fill that role, but pharmaceutical economics of a $10,000 implant don't support a cosmetic indication. The gap between tanning demand and regulated supply is real, but MT-II from a gray-market vendor isn't the answer to it. It activates the wrong receptors, comes with no quality control, darkens moles in ways that interfere with skin cancer screening, and sits in the kind of legally gray, medically unsupervised space that reliably produces bad outcomes over time. The cosmetic tanning market is waiting for a selective MC1R agonist at cosmetic-appropriate pricing; until that exists, the honest recommendation is self-tanner.